

Urinary Tract Pathogens (in Order of Frequency) - % Susceptible

| Organism | Number of Isolates | Amox clavulanic | Ampicillin | Cefazolin (1) | Ceftazidime | Ceftriaxone | Ciprofloxacin | Fosfomycin | Gentamicin | Meropenem | Nitrofurantoin | Trimethoprim- Sulfamethoxazole |
|--------------------------|--------------------------|-----------------|------------|---------------|-------------|-------------|---------------|------------|------------|-----------|----------------|-----------------------------------|
| E. coli ^ | 349 | 70 | 53 | 75 | | 79 | 51 | 95 | 93 | 100 | 95 | 72 |
| Enterococcus species ^^^ | 123 | | | | | | | | | | | |
| Klebsiella pneumoniae * | 97 | 96 | | 94 | | 96 | 89 | | 97 | 100 | 28 | 96 |
| Proteus mirabilis + | 58 | 93 | 86 | 93 | | 98 | 78 | | 97 | 100 | | 91 |
| Group B Streptococcus ^^ | <30 | | | | | | | | | | | |
| Pseudomonas aeruginosa | <30 | | | | 100 n:27 | | 81 n:27 | | 93 n:27 | | | |

Organism Notes:

- * Includes ESBL and AMP-C isolates (4.1% of total Klebsiella pneumoniae isolates identified as ESBL and AMP-C).
- ^ Includes ESBL and AMP-C isolates (20.6% of total E.coli isolates identified as ESBL and AMP-C).

^^^ Clindamycin, Trimethoprim/Sulfamethoxazole and all Cephalosporins are ineffective against Enterococcus species. Enterococcus isolates recovered from urine are generally susceptible to amoxicillin and nitrofurantoin. Susceptibility to Amoxicillin is 95.7% and to Nitrofurantoin is 94.9%

+ Includes ESBL and AMP-C isolates (1.7% of total Proteus mirabilis isolates identified as ESBL and AMP-C).

Antibiotic Notes:

(1) Cefazolin interpretation predicts results for Cephalexin (Keflex) in accordance with CLSI standards for urinary sites only (not systemic).

All Other Specimen Types excluding (Urines and Surveillance) - Organisms in Order of Frequency - % Susceptible

| Organism | Number of Isolates | Cefazolin | Ceftazidime | Ciprofloxacin | Clindamycin | Cloxacillin | Erythromycin | Gentamicin | Tetracycline (2) | Trimethoprim- Sulfamethoxazole |
|---------------------------|--------------------------|-------------|-------------|---------------|-------------|-------------|--------------|------------|------------------|-----------------------------------|
| Staphylococcus aureus ^^^ | 103 | 74 n:100 | | | 56 n:100 | 74 n:100 | 53 n:100 | | 98 n:100 | 100 n:100 |
| Pseudomonas aeruginosa | 61 | | 97 | 92 | | | | 97 | | |
| Group B Streptococcus ^^ | <30 | | | | | | | | | |

Organism Notes:

^^ This isolate is predictably susceptible to Penicillin.

^ Includes Methicillin Resistant S.aureus (MRSA). MRSA is resistant to all B-Lactams (penicillins, cephalosporins, B-lactam/B-lactamase inhibitor combinations, and carbapenems). MRSA constitutes 26.2% of total Staphylococcus aureus isolates identified.

Antibiotic Notes:

(2) Organisms that are susceptible to Tetracycline are also considered susceptible to Doxycycline.

General Notes:

Antibiogram results, patient risk factors for resistant organisms, and resistance epidemiology should be considered together to help guide empiric treatment of initial infections. Treatment should be re-evaluated as additional information from culture and sensitivity become available.

Calculation of results based on first isolate per patient.

90-100% of isolates are susceptible to the antibiotic indicated (GOOD CHOICE)

21-89% of isolates are susceptible to the antibiotic indicated (INTERMEDIATE CHOICE)

0-20% of isolates are susceptible to the antibiotic indicated (POOR CHOICE)

Value based on < 30 isolates. Statistical comparison on results with less than 30 isolates is unreliable. n = # of isolates tested.

Antibiotic susceptibility testing is not typically performed on the organism.

M This isolate is predictably susceptible to Penicillin.